Complement component iRNA compositions and methods of use thereof
US11186842B2 · kind B2 · utility
4Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2019 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Sep 18, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and/or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.